Table 4.

Treatment Emergent AIC Cases

	Patient 1	Patient 2	Patient 3*	Patient 4	Patient 5	Patient 6
Age at study entry, Gender	50’s M	70’s F	60’s M	70’s M	70’s M	70’s F
Number of prior CLL Treatments	5	0	3	6	2	0
Rai Stage	IV	I	II	IV	I	IV
Complex Karyotype	Y	N	Y	Y	Y	N
IGHV mutational status	mutated	mutated	unmutated	unknown	unmutated	unmutated
FISH panel abnormalities	BCL6 (3q27) CMYC (8q24) TP53 (17p13·1) D13S319(13q14·3)	D12Z3 (12cen)	D13S319(13q14·3) ATM (11q22·3)	none	D13S319(13q14·3) TP53 (17p13·1)	D13S319(13q14·3)
AIC prior to ibrutinib	none	none	AIHA	AIHA	AIHA	ITP
AIC therapies prior to ibrutinib	n/a	n/a	Prednisone, IVIG, Rituximab, Dexamethsone, Aranesp	Rituximab, oral cyclophosphamide, mycophenolate mofetil, IVIG, prednisone, cyclosporine	Prednisone, IVIG	None
On an AIC therapy when starting ibrutinib	n/a	n/a	No	Yes, Prednisone 10mg	Yes, Prednisone 10mg	n/a
Treatment emergent AIC type	New AIHA	New AIHA	Relapsed AIHA	Relapsed AIHA	New ITP	Relapsed ITP
AIC therapy received	Prednisone, IVIG	IVIG	IVIG	Prednisone	Prednisone	Prednisone, Dexamethasone
AIC controlled	Yes	Yes	Yes	No	Yes	No
On ibrutinib at last follow up	No	Yes	Yes	No	Yes	No
Patient outcome	Died from infection	Alive and well	Alive and well	Stopped ibrutinib due need for steroids and infections, died from infection	Alive and well	Discontinued ibrutinib due to rash

Characteristics are at time of ibrutinib initiation unless otherwise specified. Patient 3 is the only patient who received concomitant treatment with ofatumumab.

^*Developed autoimmune granulocytopenia which was treated with cyclosporine.